Company news
Imaging Biometrics Limited (LSE:IBAI) news
Imaging Biometrics Limited news releases on 6ix. Latest, May 2, 2024: IB Announces Expanded Access Program for GaM
Press releases — page 2
IB Announces Expanded Access Program for GaM
May 2, 2024
Grant of Options
March 5, 2024
Result of Broker Option and Total Voting Rights
February 26, 2024
Placing and Broker Option
February 22, 2024
FDA Application Update
February 9, 2024
IB awarded a $100,000 grant
February 2, 2024
Director Dealings and Conversion of CLNs
January 15, 2024
IB Launching an Expanded Access Program for GaM
January 10, 2024
Imaging Biometrics granted FDA “Fast-Track”
December 19, 2023
IQ-AI Announces Positive Interim Phase 1 Results
December 5, 2023
Director Dealing and Conversion of CLNs
November 9, 2023
Application for Pediatric Rare Disease Designation
November 8, 2023
Update Regarding Imaging Biometrics LLC
October 18, 2023
IB Letter to Shareholders
October 13, 2023
Orphan Drug Status to GaM and Total Voting Rights
October 9, 2023
IQ-AI shares cease trading on the OTCQB
September 19, 2023
Reduced Gadolinium Approach Validated'
September 8, 2023
Update on Collaboration Agreement with Mayo Clinic
August 18, 2023
Imaging Biometrics Installs IB Nimble™ For MCW
July 19, 2023
Orphan Drug Designation for GaM in Pediatric GBM
July 13, 2023
Studies Show GaM Inhibits Pediatric Tumor Growth
June 27, 2023
AGM Statement
May 23, 2023
Final Results
April 26, 2023
Orphan Drug Designation Status
February 28, 2023
Second Price Monitoring Extn
January 13, 2023
Letter to Shareholders
January 10, 2023
Holding in Company
December 2, 2022
Price Monitoring Extension
October 25, 2022
Issue of Warrants to Employees
September 26, 2022
TR1 - Notification of Major Holdings
August 3, 2022
Imaging Biometrics Announces Channel Partnership
July 11, 2022
Submission of FDA 510(k) Application for IB Zero G
May 31, 2022
IB Broadens Quantitative Mapping
May 3, 2022
IQAI's Sponsored Phase I Clinical Trial is Open
March 9, 2022
Total Voting Rights
February 28, 2022
Issue of shares to Mayo Clinic
February 8, 2022
Imaging Biometrics LLC - Letter to Shareholders
January 27, 2022
Director/PDMR Shareholding
January 4, 2022
IQ-AI Prepares for Phase I Clinical Trial Launch
December 17, 2021
Director's Interest
December 13, 2021
Agreement with St. Jude Children's Hospital
November 11, 2021
MD ANDERSON ADOPTS IB CLINIC
November 2, 2021
Placing
October 7, 2021
Case Report on Clinical Value of IB Software
October 1, 2021
EU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
September 22, 2021
IB Software Chosen for Accuracy and Automation
September 17, 2021
Update on Phase I Clinical Trial
September 10, 2021
Start of Trading on the OTCQB Venture Market
September 1, 2021
Half Yearly Report
August 27, 2021
IQAI Awarded "Gad-Free" Patent
June 11, 2021